Control-IQ闭环系统在1型糖尿病儿童中的延长使用研究
本研究在101名6-13岁1型糖尿病儿童中,经16周随机对照试验后,22名原传感器增强泵(SAP)组患儿启用Control-IQ闭环控制(CLC)系统(SAP-CLC队列),78名原CLC组患儿继续使用(CLC-CLC队列),再观察12周。SAP-CLC队列的葡萄糖目标范围内时间(TIR)从55±13%升至65±10%(P<0.001),低血糖时间减少;CLC-CLC队列TIR保持稳定。两队列均无糖尿病酮症酸中毒或严重低血糖发生。
要点
- SAP-CLC队列TIR从55±13%升至65±10%,第1天即见改善。
- SAP-CLC队列36%达到TIR>70%且低血糖时间<1%,SAP期为14%。
- CLC-CLC队列TIR在28周内保持稳定,无严重低血糖或DKA。
核心结论
- Control-IQ闭环系统可安全改善6-13岁1型糖尿病儿童的血糖控制,且效果从使用第1天起显现并可持续至28周。
研究设计与样本
- 研究为随机对照试验后的延长评估,共101名6-13岁1型糖尿病儿童,其中SAP-CLC队列22人、CLC-CLC队列78人,延长观察12周。
主要发现
- SAP-CLC队列TIR从55±13%升至65±10%(P<0.001),36%达到TIR>70%且低血糖时间<1%(SAP期14%,P=0.03),低血糖时间从1.80%降至1.34%(P<0.001)。
- CLC-CLC队列TIR从随机化前53±17%升至试验期67±10%,延长12周期间保持66±10%。
- 两队列均无糖尿病酮症酸中毒或严重低血糖事件。
临床怎么用
- 对于6-13岁1型糖尿病儿童,可考虑使用Control-IQ闭环系统以改善TIR并减少低血糖时间,且效果可持续。
局限性
- 原文未明确报告延长阶段的样本量计算、随访依从性及长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To further evaluate the safety and efficacy of the Control-IQ closed-loop control (CLC) system in children with type 1 diabetes. RESEARCH DESIGN AND METHODS: After a 16-week randomized clinical trial (RCT) comparing CLC with sensor-augmented pump (SAP) therapy in 101 children 6-13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks. RESULTS: In the SAP-CLC cohort, mean percentage of time in range 70-180 mg/dL (TIR) increased from 55 ± 13% using SAP during the RCT to 65 ± 10% using CLC (P < 0.001), with 36% of the cohort achieving TIR >70% plus time <54 mg/dL <1% compared with 14% when using SAP (P = 0.03). Substantial improvement in TIR was seen after the 1st day of CLC. Time <70 mg/dL decreased from 1.80% to 1.34% (P < 0.001). In the CLC-CLC cohort, mean TIR increased from 53 ± 17% prerandomization to 67 ± 10% during the RCT and remained reasonably stable at 66 ± 10% through the 12 weeks post-RCT. No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either cohort. CONCLUSIONS: This further evaluation of the Control-IQ CLC system supports the findings of the preceding RCT that use of a closed-loop system can safely improve glycemic control in children 6-13 years old with type 1 diabetes from the 1st day of use and demonstrates that these improvements can be sustained through 28 weeks of use.
引用
- Kanapka LG, Wadwa RP, Breton MD, et al. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care. 2020. PMID: 33355258. doi:10.2337/dc20-1729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。